SCHEMBL4415696

SCHEMBL4415696

O=C(Nc1ccc(N2CCOCC2)c(F)c1)C1C2CN(S(=O)(=O)Cc3ccccc3)CC21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.50
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 4/20 0.47
HTT P42858 1/20 0.46
NPY2R P49146 1/20 0.44
KDM1A O60341 1/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
DGAT1 O75907 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4551999 0.93 MAPT (0.47) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL2182097 0.90 LDHA (0.51) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4414073 0.89 IDH2 (0.46) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4427708 0.85 NPC1 (0.54) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL2181886 0.84 NPC1 (0.52) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4415701 0.84 MAPT (0.46) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4425056 0.81 KMT2A (0.48) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4423583 0.81 ALDH1A1 (0.49) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4421562 0.79 ALDH1A1 (0.47) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL4417870 0.79 ALDH1A1 (0.53) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAPT 1368/4885SMN1; SMN2 4003/4885NPC1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.